EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TNF‐α and BP180 Antibodies in Bullous Pemphigoid: Blister Fluid Dynamics and Clinical Correlations

Mahmut Can Koska, Mehmet Salih Gürel, Hayriye Erman

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/9238747 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 29.06.2026. Verfasst von Mahmut Can Koska und 2 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor necrosis factor‐alpha (TNF‐α) and anti‐BP180‐NC16A immunoglobulin G (IgG) antibodies play roles in the pathogenesis of bullous pemphigoid (BP). However, their correlation with each other, with novel disease severity scales, and their changes in blister fluids during initial therapy have not been well established.

Objectives

Objectives: Analyzing TNF‐α and anti‐BP180 antibodies in the blister fluids and sera of BP patients to explore these relationships.

Methods

This prospective study included 14 BP patients. We collected blister fluids and sera at baseline and during the initial two weeks of therapy. TNF‐α and anti‐BP180‐NC16A IgG levels were measured by using enzyme‐linked immunosorbent assay. We assessed disease severity using Bullous Pemphigoid Disease Area Index (BPDAI) and BPDAI‐pruritus scores.

Results

Our findings showed that TNF‐α levels were significantly higher in blister fluids than in serum ( p = 0.002). In contrast, anti‐BP180‐NC16A IgG levels were significantly higher in serum than in blister fluid ( p = 0.011) and showed a strong correlation ( r = 0.921, p < 0.001). A moderate correlation was found between TNF‐α and anti‐BP180‐NC16A IgG levels in blister fluid ( r = 0.600, p = 0.023), but not in serum. Blister fluid and serum anti‐BP180‐NC16A IgG levels were moderately correlated with BPDAI scores ( r = 0.575, p = 0.032 and r = 0.573, p = 0.032, respectively). However, neither TNF‐α nor anti‐BP180 antibodies correlated with severity subgroups or BPDAI‐pruritus scores. Blister fluid TNF‐α showed a trend toward decreased levels during the first week of therapy. No significant changes were observed in serum samples during the first two weeks of treatment.

Conclusion

TNF‐α may be associated with humoral immunity at tissue level and reflect local inflammatory process. TNF‐α levels in new blisters that appear during initial therapy may be affected. While BP180 antibodies seem associated with BPDAI, they do not correlate with severity subgroups or pruritus. Serum markers in the early treatment period may not be useful for predicting disease progression. Trial Registration: ClinicalTrials.gov_identifier: NCT03856840

Zitieren

APA

Koska, M. C., Gürel, M. S., & Erman, H. (2026). TNF‐α and BP180 Antibodies in Bullous Pemphigoid: Blister Fluid Dynamics and Clinical Correlations. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/9238747

Vancouver

Koska MC, Gürel MS, Erman H. TNF‐α and BP180 Antibodies in Bullous Pemphigoid: Blister Fluid Dynamics and Clinical Correlations. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/9238747

BibTeX
@article{Koska2026,
  author = {Koska, Mahmut Can and Gürel, Mehmet Salih and Erman, Hayriye},
  title = {TNF‐α and BP180 Antibodies in Bullous Pemphigoid: Blister Fluid Dynamics and Clinical Correlations},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/9238747}
}
Kostenlos starten →